Literature DB >> 11897603

Activity of BMS-284756, a novel des-fluoro(6) quinolone, against Staphylococcus aureus, including contributions of mutations to quinolone resistance.

D E Low1, M Muller, C L Duncan, B M Willey, J C de Azavedo, A McGeer, B N Kreiswirth, S Pong-Porter, D J Bast.   

Abstract

The in vitro activity of BMS-284756 against 602 Staphylococcus aureus isolates, including 152 that were both methicillin and ciprofloxacin resistant (MIC > or = 4 microg/ml), was determined. For ciprofloxacin-susceptible and nonsusceptible isolates, the MICs at which 50% of organisms were inhibited were 0.015 and 2 microg/ml and the MICs at which 90% of organisms were inhibited were 0.03 and 4 microg/ml, respectively.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 11897603      PMCID： PMC127112          DOI： 10.1128/AAC.46.4.1119-1121.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

1.  Antibacterial spectrum of a novel des-fluoro(6) quinolone, BMS-284756.

Authors:  J C Fung-Tomc; B Minassian; B Kolek; E Huczko; L Aleksunes; T Stickle; T Washo; E Gradelski; L Valera; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

2.  Characterization of grlA, grlB, gyrA, and gyrB mutations in 116 unrelated isolates of Staphylococcus aureus and effects of mutations on ciprofloxacin MIC.

Authors:  F J Schmitz; M E Jones; B Hofmann; B Hansen; S Scheuring; M Lückefahr; A Fluit; J Verhoef; U Hadding; H P Heinz; K Köhrer
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

Review 3.  Mechanisms of action of antimicrobials: focus on fluoroquinolones.

Authors:  D C Hooper
Journal:  Clin Infect Dis       Date:  2001-03-15       Impact factor: 9.079

4.  Activities of trovafloxacin compared with those of other fluoroquinolones against purified topoisomerases and gyrA and grlA mutants of Staphylococcus aureus.

Authors:  T D Gootz; R P Zaniewski; S L Haskell; F S Kaczmarek; A E Maurice
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

5.  Quinolone resistance in Staphylococci: activities of new nonfluorinated quinolones against molecular targets in whole cells and clinical isolates.

Authors:  S Roychoudhury; C E Catrenich; E J McIntosh; H D McKeever; K M Makin; P M Koenigs; B Ledoussal
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

6.  Mechanisms of fluoroquinolone resistance.

Authors:  David C. Hooper
Journal:  Drug Resist Updat       Date:  1999-02       Impact factor: 18.500

7.  Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada. Canadian Bacterial Surveillance Network.

Authors:  D K Chen; A McGeer; J C de Azavedo; D E Low
Journal:  N Engl J Med       Date:  1999-07-22       Impact factor: 91.245

8.  Staphylococcus aureus mutants selected by BMS-284756.

Authors:  L F Discotto; L E Lawrence; K L Denbleyker; J F Barrett
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

9.  Efflux-mediated fluoroquinolone resistance in Staphylococcus aureus.

Authors:  G W Kaatz; S M Seo; C A Ruble
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191
  9 in total
  8 in total

Review 1.  In vitro antibacterial activity and pharmacodynamics of new quinolones.

Authors:  A Dalhoff; F-J Schmitz
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2003-04-01       Impact factor: 3.267

2.  Increasing prevalence of methicillin-resistant Staphylococcus aureus causing nosocomial infections at a university hospital in Taiwan from 1986 to 2001.

Authors:  Po-Ren Hsueh; Lee-Jene Teng; Wen-Hwei Chen; Huei-Ju Pan; Mei-Lin Chen; Shan-Chwen Chang; Kwen-Tay Luh; Fang-Yue Lin
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

3.  The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase.

Authors:  Sachin S Bhagwat; Lakshmi A Mundkur; Shrikant V Gupte; Mahesh V Patel; Habil F Khorakiwala
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

4.  In vitro and in vivo antibacterial activities of heteroaryl isothiazolones against resistant gram-positive pathogens.

Authors:  Michael J Pucci; Jijun Cheng; Steven D Podos; Christy L Thoma; Jane A Thanassi; Douglas D Buechter; Gohar Mushtaq; Gerald A Vigliotti; Barton J Bradbury; Milind Deshpande
Journal:  Antimicrob Agents Chemother       Date:  2007-01-22       Impact factor: 5.191

5.  In vitro and in vivo profiles of ACH-702, an isothiazoloquinolone, against bacterial pathogens.

Authors:  Michael J Pucci; Steven D Podos; Jane A Thanassi; Melissa J Leggio; Barton J Bradbury; Milind Deshpande
Journal:  Antimicrob Agents Chemother       Date:  2011-04-04       Impact factor: 5.191

6.  Pharmacodynamic modeling of the evolution of levofloxacin resistance in Staphylococcus aureus.

Authors:  Jeffrey J Campion; Philip Chung; Patrick J McNamara; William B Titlow; Martin E Evans
Journal:  Antimicrob Agents Chemother       Date:  2005-06       Impact factor: 5.191

7.  Mutant prevention concentration of garenoxacin (BMS-284756) for ciprofloxacin-susceptible or -resistant Staphylococcus aureus.

Authors:  Xilin Zhao; William Eisner; Nathan Perl-Rosenthal; Barry Kreiswirth; Karl Drlica
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

8.  Dual targeting of DNA gyrase and topoisomerase IV: target interactions of heteroaryl isothiazolones in Staphylococcus aureus.

Authors:  Jijun Cheng; Jane A Thanassi; Christy L Thoma; Barton J Bradbury; Milind Deshpande; Michael J Pucci
Journal:  Antimicrob Agents Chemother       Date:  2007-05-14       Impact factor: 5.191
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.